1 / 21

Chapter 11: Sequential Clinical Trials

Chapter 11: Sequential Clinical Trials. Descriptive Exploratory Experimental Describe Find Cause Populations Relationships and Effect Sequential Clinical Trials.

kadeem
Download Presentation

Chapter 11: Sequential Clinical Trials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chapter 11:Sequential Clinical Trials Descriptive ExploratoryExperimental Describe Find Cause PopulationsRelationships and Effect Sequential Clinical Trials

  2. Sequential Clinical Trials Experimental designs – • Relative efficacy of different treatments (cause and effect) • Problems: 1. Fixed sample size prior 2. All data must be collected prior to analysis

  3. The Design of a Sequential Trial • Purpose- • To compare two treatments: • New Treatment (experimental)- A • Old Treatment (standard)- B • Null hypothesis A = B • Explicit operational definitions, target population, and measurements are established

  4. Between-Subject Comparison • First eligible patient admitted and is randomly assigned to either treatment A or B • Second eligible patient is admitted and is assigned to the alternate treatment • These two patients form a pair • Results of the pair are considered “little experiment”as we can determine for this pair whether A or B was better

  5. Within- Subject Comparison • The comparison between A and B can be made on one subject when both treatments are presented to each subject • This approach is only appropriate when there are no carry over effects expected from one treatment to another • Usually, alternate pairs are given the treatments in reverse order, resulting in a crossover design • Crossover design reduces intersubject variability

  6. Design- continued • The whole experiment is a sequence of these “little experiments”with each pair represents a comparison • The comparison between A and B can be measured in two ways: • Continuous variable- the magnitude of the difference • Nominal (discrete) variable- the preference measured by a subjective, yet, clearly defined criteria indicating that one treatment is more effective than the other

  7. Sequential Chart • Results of each comparison within a pair of subjects are plotted on a sequential chart showing the cumulative results for all comparisons • After each successive “little experiment”is plotted the researcher stops to consider the results of all pairs completed so far and make one of the following three decisions:

  8. Decision Making 1. Stop and reject Nullhypothesis making a terminal decision to recommend A or B 2. Stop and accept Nullhypothesis making a terminal decision that there is no difference between A or B 3. Continue to collect data because the cumulated data are not yet sufficient to draw a conclusion • The process of considering cumulative results after each pair is called“sequential analysis”

  9. Measuring Preference • Preference is defined on the basis of clinically meaningful differences between two treatments • Specific criteria for preference of one treatment over the other can vary in objectivity Objective Criteria • Death Vs. Survival • Cured Vs. Not cured

  10. Measuring Preference Subjective Criteria • Subjective evaluation of function • Patient’s general reaction to treatment Measuring Preference- Continuous Data Can be reduced to Nominal Data Treatment A preferred if it: Increases ROM at least 20 degrees more than Treatment B

  11. Measuring Preference • Drawback: • Difference either 25 or 75 degrees is considered as difference • When the difference is based on Magnitude, the amount of difference is taken into account

  12. Measuring Preference

  13. Sequential Plans for Evaluating Preference • The decision to stop or continue a trail is based on “little experiments” Stopping Rules: • Upper boundary crossed (U), recommend A Terminal decision: Accept H1 : A>B

  14. Sequential Plans for Evaluating Trials 2. Lower boundary crossed (L), recommend B Terminal decision: Accept H1 B>A 3. Middle boundary crossed (M), either above or bellow the origin, no preference Terminal Decision: Accept H0: A=B Figure 11-2

  15. Effect Size • Preference is described according to the proportion in favor of Treatment A (the experimental treatment) • Under H0- this proportion is 50% for each treatment • Under Hr- this proportion is some value above 50% • If we set effect size at 0.80, we expect at least 80% of preferences to be for A before recommending Treatment A

  16. Type I Error • The acceptable risk of recommending one treatment over the other when treatment A and B are not different • Type I Error rate is the probability of incorrectly rejecting the Null hypothesis (no difference), and accepting the Research hypothesis • The risk is symbolized by ά (alpha) and is set at .05

  17. Type I Error • Alpha can designate: • a one-tailed test (ά1) directional research hypothesis or a two-tailed test (ά2) non directional research hypothesis

  18. Type II Error • The probability of incorrectly accepting Null hypothesis (no difference), when rejecting research hypothesis (there is a difference between A and B), yet the analysis was not able to detect it. • This risk is symbolized by β (beta) and is set between 0.05 and 0.20

  19. Power • The probability that a statistical test will be able to detect a true difference between A and B. • Power is equal to 1-β • If β= .05; power = .95 • This means that there will be 95% chance that an outer boundary will be correctly crossed • Figure 11-2, page 207, 208

  20. Limitations of Sequential Designs • The analysis is limited to two treatments • No opportunity to explore multiple effects or interaction effects • No opportunity to control for extraneous variables • Treatment of ties • Conditional decision vs. terminal decision (based on boundary crossing)

  21. Sequential Clinical Trials • Now you know all about sequential clinical trials!!!!

More Related